Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Operating Leases (2019 - 2025)

Guided Therapeutics (GTHP) has disclosed Operating Leases for 7 consecutive years, with $651000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 320.0% to $651000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $651000.0 through Dec 2025, up 320.0% year-over-year, with the annual reading at $651000.0 for FY2025, 320.0% up from the prior year.
  • Operating Leases hit $651000.0 in Q4 2025 for Guided Therapeutics, up from $76000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $651000.0 in Q4 2025 to a low of $377.0 in Q1 2022.
  • Historically, Operating Leases has averaged $264388.3 across 5 years, with a median of $267000.0 in 2022.
  • Biggest five-year swings in Operating Leases: plummeted 99.9% in 2022 and later skyrocketed 59581.7% in 2023.
  • Year by year, Operating Leases stood at $325000.0 in 2021, then changed by 0.0% to $325000.0 in 2022, then fell by 24.31% to $246000.0 in 2023, then crashed by 36.99% to $155000.0 in 2024, then soared by 320.0% to $651000.0 in 2025.
  • Business Quant data shows Operating Leases for GTHP at $651000.0 in Q4 2025, $76000.0 in Q3 2025, and $130000.0 in Q1 2025.